| Handling covariates in the design of clinical trials WF Rosenberger, O Sverdlov Statistical Science 23 (3), 404-419, 2008 | 194 | 2008 |
| Digital therapeutics: an integral component of digital innovation in drug development O Sverdlov, J Van Dam, K Hannesdottir, T Thornton‐Wells Clinical Pharmacology & Therapeutics 104 (1), 72-80, 2018 | 148 | 2018 |
| Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile … G Tong, JS Wang, O Sverdlov, SP Huang, R Slemmon, R Croop, ... Clinical therapeutics 34 (3), 654-667, 2012 | 91 | 2012 |
| Adaptive randomization for clinical trials WF Rosenberger, O Sverdlov, F Hu Journal of biopharmaceutical statistics 22 (4), 719-736, 2012 | 83 | 2012 |
| Pharmacodynamics of selective inhibition of γ-secretase by avagacestat CF Albright, RC Dockens, JE Meredith, RE Olson, R Slemmon, KA Lentz, ... Journal of Pharmacology and Experimental Therapeutics 344 (3), 686-695, 2013 | 77 | 2013 |
| A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects R Dockens, JS Wang, L Castaneda, O Sverdlov, SP Huang, R Slemmon, ... Clinical pharmacokinetics 51, 681-693, 2012 | 53 | 2012 |
| Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men G Tong, L Castaneda, JS Wang, O Sverdlov, SP Huang, R Slemmon, ... Clinical drug investigation 32, 761-769, 2012 | 46 | 2012 |
| Optimal response‐adaptive randomized designs for multi‐armed survival trials O Sverdlov, Y Tymofyeyev, WK Wong Statistics in medicine 30 (24), 2890-2910, 2011 | 46 | 2011 |
| Modern adaptive randomized clinical trials: statistical and practical aspects O Sverdlov CRC Press, 2015 | 45 | 2015 |
| A roadmap to using randomization in clinical trials VW Berger, LJ Bour, K Carter, JJ Chipman, CC Everett, N Heussen, ... BMC medical research methodology 21, 1-24, 2021 | 44 | 2021 |
| On recent advances in optimal allocation designs in clinical trials O Sverdlov, WF Rosenberger Journal of Statistical Theory and Practice 7, 753-773, 2013 | 44 | 2013 |
| Adaptive clinical trial designs for phase I cancer studies O Sverdlov, WK Wong, Y Ryeznik | 33 | 2014 |
| Utility of covariate-adjusted response-adaptive randomization in survival trials O Sverdlov, WF Rosenberger, Y Ryeznik Statistics in Biopharmaceutical Research 5 (1), 38-53, 2013 | 27 | 2013 |
| A comparative study of restricted randomization procedures for multiarm trials with equal or unequal treatment allocation ratios Y Ryeznik, O Sverdlov Statistics in Medicine 37 (21), 3056-3077, 2018 | 23 | 2018 |
| Randomization in clinical trials: can we eliminate bias? O Sverdlov, WF Rosenberger Clinical Investigation 3 (1), 37-47, 2013 | 23 | 2013 |
| An overview of healthcare data analytics with applications to the COVID-19 pandemic Z Fei, Y Ryeznik, O Sverdlov, CW Tan, WK Wong IEEE Transactions on Big Data 8 (6), 1463-1480, 2021 | 22 | 2021 |
| A study of novel exploratory tools, digital technologies, and central nervous system biomarkers to characterize unipolar depression O Sverdlov, J Curcic, K Hannesdottir, L Gou, V De Luca, F Ambrosetti, ... Frontiers in psychiatry 12, 640741, 2021 | 21 | 2021 |
| Efficient and ethical response-adaptive randomization designs for multi-arm clinical trials with Weibull time-to-event outcomes O Sverdlov, Y Ryeznik, WK Wong Journal of Biopharmaceutical Statistics 24 (4), 732-754, 2014 | 21 | 2014 |
| A smartphone-based intervention as an adjunct to standard-of-care treatment for schizophrenia: randomized controlled trial SN Ghaemi, O Sverdlov, J van Dam, T Campellone, R Gerwien JMIR formative research 6 (3), e29154, 2022 | 20 | 2022 |
| Citalopram for acute and preventive efficacy in bipolar depression (CAPE-BD): a randomized, double-blind, placebo-controlled trial SN Ghaemi, EA Whitham, PA Vohringer, SA Barroilhet, A Amerio, ... The Journal of Clinical Psychiatry 82 (1), 6067, 2021 | 20 | 2021 |
Yevgen Ryeznik, Ph. D.Researcher in Statistics & Pharmacometrics, Department of Pharmacy, Uppsala UniversityVerified email at farmaci.uu.se
